Laboratory assays evaluating the effect of DNA sequence variants on BRCA1 mRNA splicing may contribute to classification by providing molecular evidence. However, our knowledge of normal and aberrant BRCA1 splicing events to date has been limited to data derived from assays targeting partial transcript sequences. For the first time, we resolve the exon structure of whole BRCA1 transcripts using MinION nanopore sequencing of long-range PCR amplicons. Our study identified 32 BRCA1 isoforms, including 18 novel isoforms which comprised skipping of multiple contiguous and/or non-contiguous exons. Furthermore, we show that known BRCA1 exon skipping events, such as Δ (9,10) and Δ 21, can co-occur in a single transcript, with some isoforms containing four or more alternative splice junctions. Our results highlight complexity in BRCA1 transcript structure that has not previously been described. This finding has key implications for predicting translation frame of splicing transcripts, important for interpreting the clinical significance of spliceogenic variants. Future research is warranted to quantitatively assess full length BRCA1 transcript levels, and to assess the application of nanopore sequencing for routine evaluation of potential spliceogenic variants.
Introduction
Routine diagnostic screening for deleterious variants in the breast cancer susceptibility gene BRCA1 is typically performed for individuals from suspected high-risk breast (and ovarian) cancer families to identify the genetic cause for their disease. However, an important practical issue associated with genetic testing is the identification of rare sequence variants with unknown clinical significance. Interpreting the clinical meaning of unclassified variants is a key challenge facing the future of genomic-based health initiatives. 1 Multifactorial likelihood analysis is the most accepted approach for assessing cancer risk associated with unclassified BRCA1 variants and has been successful in classifying hundreds of variants since it was developed 2, 3 (http://brcaexchange.org/). However, the multifactorial likelihood model is limited by the amount of information available from the variant carrier (tumour histopathology), the family of the variant carrier (co-segregation, family history information) and additional information, such as co-occurrence with a pathogenic variant.
Numerous studies have shown that the effect of a variant of unknown clinical significance on BRCA1 mRNA splicing may contribute to classification by offering molecular evidence. [4] [5] [6] [7] Moreover, to classify variants using a combination of bioinformatic and in vitro splicing data, Spurdle et al. (2008) 8 proposed 5-tier splicing classification (Class 5-pathogenic, Class 4likely pathogenic, Class 3-uncertain, Class 2-likely not pathogenic, Class 1-not pathogenic) guidelines. These guidelines were subsequently improved after a multicentre study carried out by the international ENIGMA consortium. 6 Determining which mRNA splice isoforms are abnormal and potentially deleterious can be challenging. The ENIGMA Splicing Working Group recently undertook a comprehensive analysis to characterize numerous 'naturally occurring' mRNA splice isoforms for BRCA1 to aid in the interpretation of in vitro splicing assays. 9 This study identified more than 60 BRCA1 mRNA isoform events occurring in breast and/or blood cells. However, it remains unclear whether these individual splicing events can co-occur in the same BRCA1 transcript, as PCR-and sequencing-based technologies used to assess splicing events typically interrogate only a fraction of the whole transcript(s). Pathogenic (or Class 5) variants that cause mRNA splicing changes are expected to disrupt protein function either through truncation or in-frame deletion of important regions of the encoded proteins. Using technologies that only examine a section of mRNA transcripts for variant classification may therefore lead to a misinterpretation of in-frame or out-of-frame splicing events.
DNA sequencing technology based on nanopore sequencing generates read lengths that greatly exceed those of more commonly used Sanger sequencing and massively parallel sequencing platforms. Moreover, nanopore sequencing has been demonstrated to characterise the complex exon structure of mRNA transcripts from genes expressing a large number of isoforms. 10 To our knowledge, single-molecule sequencing technologies (MinION 11 and PacBio 12 ) that enable long sequence reads have yet to be employed to resolve the exon structure of whole BRCA1 mRNA transcripts. In this study, we explored the utility of longrange reverse transcriptase (RT)-PCR with nanopore sequencing to identify novel BRCA1 isoforms and the co-occurrence of known exon skipping events.
Results and Discussion

PCR amplification of full-length BRCA1 cDNA
Lymphoblastoid cell lines (LCLs) have been widely used as a cell model for evaluating BRCA1 splicing changes. 9 For this study, we assessed RNA from a healthy control LCL that was previously used for an international workshop, led by the ENIGMA Consortium, that compared mRNA splicing assay protocols between laboratories. 7 To obtain full length BRCA1 transcripts, we carried out long-range RT-PCR for BRCA1 transcripts using primers targeting the 3' end of exon 1 and the 5' end of exon 24 to generate a 5.8kb amplicon (Supplementary Figure 1 ). Amplified products from repeat assays for a single LCL were visualised by gel electrophoresis, revealing a difference in patterns of amplicon sizes and suggesting variability in isoform selection and amplification during the PCR cycles ( Figure 1 ;
Supplementary Figure S2 ). PCR products that were consistent by size with a full-length BRCA1 isoform (NM_007294.3: encoding the full-length BRCA1 protein) were observed in 28/47 PCR assays. To generate a sequencing catalogue of whole BRCA1 transcripts, amplified products were pooled from all 47 PCR assays using cDNA synthesised from a single LCL RNA sample. A preliminary assessment of fragments from 10 PCR assays by Sanger sequencing confirmed BRCA1 identity ( Figure 1 ) prior to sequencing using the MinION.
BRCA1 isoform discovery and annotation
The first MinION sequencing run with R9 flow-cell chemistry using pooled RT-PCR products produced a total of 105,482 reads, of which 23,978 passed the quality control filters for 2D reads by Metrichor analysis. Of the total, 4,302 aligned to BRCA1 in BLAT analysis, (and 54,505 aligned to another targeted gene sequence as part of a separate study), leaving 46,675 unaligned. The second MinION sequencing run produced a total of 12,022 reads, of which 995 passed the quality control filters for 2D reads by Metrichor analysis and 11,027 failed. As expected, the number of reads failing the 2D filter equated to 40-50% of output read numbers, presumably due to shearing of DNA by pipetting or incomplete ligation of hairpin adaptors, thus resulting in shorter reads lacking a complementary strand signal.
A total of 32 BRCA1 isoforms (including full-length; Figure 2 ) were resolved with at least one sequencing read using a conservative mapping approach ( Table 1) . Of these, 20 isoforms have not been previously described. Of the 32 isoforms amplified by long-range RT-PCR, 23 lacked all or part of the largest BRCA1 exon (exon 11; 3426 bases) ( Table 1 ). Ten of these 23 isoforms contained a Δ 11q splicing event rather than the complete skipping of exon 11. This results suggest that long-range RT-PCR assays were selective for shorter amplicons corresponding to smaller (<4kb) isoforms and that the sequencing results from the MinION may not be quantitative. The remaining nine of the detected transcripts were greater than 5kb in length and included the full length and Δ 9,10 isoforms (Table 1) , which have previously been shown to be 'predominant' transcripts in blood and breast cells using semi-quantitative measures. 9 It is therefore possible that amplicon selection during long-range RT-PCR cycles may also have been influenced by the relatively high proportion of transcript levels in a pool of BRCA1 expressed isoforms.
Colombo et al previously characterized a total of 63 BRCA1 alternative splicing events 9 , 17 of which were detected and further validated in this study. Eighteen of the 20 full-length novel isoforms identified by MinION sequencing were found to contain co-occurring exon skipping events ( Table 1) . Many of these events were found to co-occur, such as Δ (9,10), Δ 11q, Δ (9,10,11q), and Δ 3, have been previously identified in isolation using partial transcript analyses by Colombo et al. 9 Of the 20 novel isoforms discovered in this study, 14 were formed entirely from a combination of previously identified alternative splice junctions (Table 1) . While these data show that many non-contiguous exon skipping events for BRCA1 mRNA occur concurrently, this analysis was non-quantitative and therefore was unable to establish the relative levels of different transcripts.
Two novel isoforms identified, give rise to functional proteins as they lack the BRCA1 C-terminal (BCRT) domain (Table   1 ). Furthermore, the out-of-frame coding sequences for these isoforms suggest that they would be susceptible to nonsense mediated decay (NMD). 13 The novel Δ 10-17 isoform was selected for validation by Sanger sequencing as the isoform was common within the PCR amplicon library, and had a single junction which was relatively straightforward to amplify. RT-PCR assays using oligonucleotide primers targeting the exon 9-18 junction, followed by Sanger sequencing, confirmed the presence of this novel isoform ( Figure 3 ).
Together, these results suggest complexity in transcript structure that has not previously been described for BRCA1. Due to the potential error rate of the MinION (>10%) 14 , a higher read depth would increase the confidence in 19 of the 32 characterised transcripts represented by a relatively small number (n≤3) of reads, and this would be particularly important for potential splice shift events not previously identified.
Co-occurring splicing events and interpretation for variant classification
Determining whether BRCA1 transcripts lead to abnormal and potentially deleterious proteins requires knowledge about the structure of the coding isoforms. Sixteen of the 20 novel isoforms lacked sequences coding for the RING and/or BCRT domains, which have been previously shown to harbour amino acid residues of clinical importance 15 , although 14 of these 16 isoforms are out-of-frame and would therefore be susceptible to NMD. The remaining two isoforms (Δ(10,11,17) and Δ (5,9,10,11q) ) are predicted to be in-frame and may potentially give rise to proteins lacking the clinically significant BCRT and RING domains, respectively.
We detected the predominant splicing events, Δ 11q and Δ 9,10, which individually would be predicted to generate modified in-frame transcripts that are not considered deleterious based on protein coding. However, our study has shown these splicing events can co-occur with skipping and insertion events causing out-of-frame coding in these isoforms (Table 1) While our work highlights that many BRCA1 mRNA splicing events occur concurrently, our non-quantitative study was unable to establish the likelihood of such events being expressed in the same transcript. If future studies show that many of the detected BRCA1 exon skipping events exclusively co-occur then the total number of isoforms might be lower than the number of events previously reported by Colombo et al. 9 Such a finding would suggest similar splicing patterns may also exist for genes other than BRCA1. Further studies will therefore be required to measure the cellular levels of sequenced isoforms, and to investigate the possibility of further transcript complexity due to splice site shifts involving a small number of nucleotides. Such studies will require improved data analysis tools to take full advantage of the sequencing information generated, although we note that this field continues to advance as evidenced by a recent report by Hu et al 16 .
The ENIGMA Splicing Working Group previously led a multi-centre study which highlighted methodological issues that confounded the interpretation of splicing results 6 . A major reason for these issues was determined to be PCR assay design and the restrictive positioning of primers which prevented detection of additional naturally occurring isoforms.
Our follow-up study has been successful in demonstrating the capability of the MinION device to characterize the exon structure of whole BRCA1 transcripts. Together, our results highlight the potential of this technology to overcome limitations of traditional PCR-based techniques.
Conclusion
Our study highlights complexity in BRCA1 transcript structure that has not been described by previously reported studies. Assessment of whole BRCA1 transcripts is now possible and has key implications for predicting translation frame of splicing transcripts, which is important for interpreting the clinical significance of spliceogenic variants. Future research is warranted to quantitatively assess full length BRCA1 transcript levels, to detect additional novel isoforms involving small nucleotide shifts and to assess the application of nanopore sequencing for routine evaluation of potential spliceogenic variants. Furthermore, the application of the MinION or similar platforms may be extended to other disease associated genes to establish if they display similar complex splicing patterns to BRCA1. 
